4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      microRNA‐132 is overexpressed in glia in temporal lobe epilepsy and reduces the expression of pro‐epileptogenic factors in human cultured astrocytes

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Temporal lobe epilepsy (TLE) is a chronic neurological disease in humans, which is refractory to pharmacological treatment in about 30% of the patients. Reactive glial cells are thought to play a major role during the development of epilepsy (epileptogenesis) via regulation of brain inflammation and remodeling of the extracellular matrix (ECM). These processes can be regulated by microRNAs (miRs), a class of small non‐coding RNAs, which can control entire gene networks at a post‐transcriptional level. The expression of miRs is known to change dynamically during epileptogenesis. miR‐132 is one of the most commonly upregulated miRs in animal TLE models with important roles shown in neurons. However, the possible role of miR‐132 in glia remains largely unknown. The aim of this study was to characterize the cell‐type specific expression of miR‐132 in the hippocampus of patients with TLE and during epileptogenesis in a rat TLE model. Furthermore, the potential role of miR‐132 was investigated by transfection of human primary cultured astrocytes that were stimulated with the cytokines IL‐1β or TGF‐β1. We showed an increased expression of miR‐132 in the human and rat epileptogenic hippocampus, particularly in glial cells. Transfection of miR‐132 in human primary astrocytes reduced the expression of pro‐epileptogenic COX‐2, IL‐1β, TGF‐β2, CCL2, and MMP3. This suggests that miR‐132, particularly in astrocytes, represents a potential therapeutic target that warrants further in vivo investigation.

          Main Points

          • miR‐132 expression is increased in the epileptogenic human and rat hippocampus.

          • miR‐132 is expressed by reactive glia.

          • miR‐132 attenuates expression of pro-epileptogenic factors in cultured human astrocytes.

          Related collections

          Most cited references39

          • Record: found
          • Abstract: found
          • Article: not found

          A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis.

          MicroRNAs (miRNAs) regulate cellular fate by controlling the stability or translation of mRNA transcripts. Although the spatial and temporal patterning of miRNA expression is tightly controlled, little is known about signals that induce their expression nor mechanisms of their transcriptional regulation. Furthermore, few miRNA targets have been validated experimentally. The miRNA, miR132, was identified through a genome-wide screen as a target of the transcription factor, cAMP-response element binding protein (CREB). miR132 is enriched in neurons and, like many neuronal CREB targets, is highly induced by neurotrophins. Expression of miR132 in cortical neurons induced neurite outgrowth. Conversely, inhibition of miR132 function attenuated neuronal outgrowth. We provide evidence that miR132 regulates neuronal morphogenesis by decreasing levels of the GTPase-activating protein, p250GAP. These data reveal that a CREB-regulated miRNA regulates neuronal morphogenesis by responding to extrinsic trophic cues.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers.

            Matrix metalloproteinases are versatile endopeptidases with many different functions in the body in health and disease. In the brain, matrix metalloproteinases are critical for tissue formation, neuronal network remodeling, and blood-brain barrier integrity. Many reviews have been published on matrix metalloproteinases before, most of which focus on the two best studied matrix metalloproteinases, the gelatinases MMP-2 and MMP-9, and their role in one or two diseases. In this review, we provide a broad overview of the role various matrix metalloproteinases play in brain disorders. We summarize and review current knowledge and understanding of matrix metalloproteinases in the brain and at the blood-brain barrier in neuroinflammation, multiple sclerosis, cerebral aneurysms, stroke, epilepsy, Alzheimer's disease, Parkinson's disease, and brain cancer. We discuss the detrimental effects matrix metalloproteinases can have in these conditions, contributing to blood-brain barrier leakage, neuroinflammation, neurotoxicity, demyelination, tumor angiogenesis, and cancer metastasis. We also discuss the beneficial role matrix metalloproteinases can play in neuroprotection and anti-inflammation. Finally, we address matrix metalloproteinases as potential therapeutic targets. Together, in this comprehensive review, we summarize current understanding and knowledge of matrix metalloproteinases in the brain and at the blood-brain barrier in brain disorders.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs.

              Animal models for seizures and epilepsy have played a fundamental role in advancing our understanding of basic mechanisms underlying ictogenesis and epileptogenesis and have been instrumental in the discovery and preclinical development of novel antiepileptic drugs (AEDs). However, there is growing concern that the efficacy of drug treatment of epilepsy has not substantially improved with the introduction of new AEDs, which, at least in part, may be due to the fact that the same simple screening models, i.e., the maximal electroshock seizure (MES) and s.c. pentylenetetrazole (PTZ) seizure tests, have been used as gatekeepers in AED discovery for >6 decades. It has been argued that these old models may identify only drugs that share characteristics with existing drugs, and are unlikely to have an effect on refractory epilepsies. Indeed, accumulating evidence with several novel AEDs, including levetiracetan, has shown that the MES and PTZ models do not identify all potential AEDs but instead may fail to discover compounds that have great potential efficacy but work through mechanisms not tested by these models. Awareness of the limitations of acute seizure models comes at a critical crossroad. Clearly, preclinical strategies of AED discovery and development need a conceptual shift that is moving away from using models that identify therapies for the symptomatic treatment of epilepsy to those that may be useful for identifying therapies that are more effective in the refractory population and that may ultimately lead to an effective cure in susceptible individuals by interfering with the processes underlying epilepsy. To realize this goal, the molecular mechanisms of the next generation of therapies must necessarily evolve to include targets that contribute to epileptogenesis and pharmacoresistance in relevant epilepsy models. Copyright © 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                e.a.vanvliet@uva.nl
                Journal
                Glia
                Glia
                10.1002/(ISSN)1098-1136
                GLIA
                Glia
                John Wiley & Sons, Inc. (Hoboken, USA )
                0894-1491
                1098-1136
                13 August 2019
                January 2020
                : 68
                : 1 ( doiID: 10.1002/glia.v68.1 )
                : 60-75
                Affiliations
                [ 1 ] Amsterdam UMC, University of Amsterdam Department of (Neuro)Pathology, Amsterdam Neuroscience, Meibergdreef 9 Amsterdam the Netherlands
                [ 2 ] Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Neurosurgery, Amsterdam Neuroscience, De Boelelaan 1117 Amsterdam the Netherlands
                [ 3 ] Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam Amsterdam the Netherlands
                [ 4 ] Stichting Epilepsie Instellingen Nederland (SEIN) Heemstede the Netherlands
                Author notes
                [*] [* ] Correspondence

                Erwin A. van Vliet, Amsterdam University Medical Centers, Location Academic Medical Center, Dept. (Neuro)Pathology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.

                Email: e.a.vanvliet@ 123456uva.nl

                Author information
                https://orcid.org/0000-0002-8313-6282
                https://orcid.org/0000-0002-4842-0659
                https://orcid.org/0000-0002-0532-4798
                https://orcid.org/0000-0002-0671-857X
                https://orcid.org/0000-0003-3842-1700
                https://orcid.org/0000-0001-5747-3202
                https://orcid.org/0000-0002-3542-3770
                Article
                GLIA23700
                10.1002/glia.23700
                6899748
                31408236
                0ecabd97-9236-4843-a688-a3d29c8f0da0
                © 2019 The Authors. Glia published by Wiley Periodicals, Inc.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 11 May 2019
                : 29 July 2019
                : 30 July 2019
                Page count
                Figures: 5, Tables: 3, Pages: 16, Words: 12407
                Funding
                Funded by: Epilepsiefonds , open-funder-registry 10.13039/501100006117;
                Award ID: 16‐05
                Funded by: FP7 Health , open-funder-registry 10.13039/100011272;
                Award ID: 602102
                Funded by: H2020 Marie Skłodowska‐Curie Actions , open-funder-registry 10.13039/100010665;
                Award ID: 642881
                Categories
                Research Article
                Research Articles
                Custom metadata
                2.0
                January 2020
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.2 mode:remove_FC converted:05.12.2019

                Neurosciences
                epileptogenesis,il‐1 beta,mirna,neuroinflammation,tgf‐beta
                Neurosciences
                epileptogenesis, il‐1 beta, mirna, neuroinflammation, tgf‐beta

                Comments

                Comment on this article